Holen Sie sich die Stockscreener-App
6.49
0.61%
-0.04
Handel nachbörslich:
6.50
0.010
+0.15%
Schlusskurs vom Vortag:
$6.53
Offen:
$6.6
24-Stunden-Volumen:
1.26M
Relative Volume:
1.39
Marktkapitalisierung:
$567.95M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-95.90M
KGV:
-4.9167
EPS:
-1.32
Netto-Cashflow:
$-79.09M
1W Leistung:
+14.46%
1M Leistung:
+32.45%
6M Leistung:
+59.07%
1J Leistung:
-3.42%
1-Tages-Spanne:
$6.45
$6.82
1-Wochen-Bereich:
$5.34
$6.82
52-Wochen-Spanne:
$1.865
$11.40
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
Firmenname
Terns Pharmaceuticals Inc
Sektor
Branche
Telefon
650-525-5535 EXT.101
Adresse
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Vergleichen Sie TERN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TERN
Terns Pharmaceuticals Inc
|
6.49 | 571.45M | 0 | -95.90M | -79.09M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2024-10-31 | Eingeleitet | Oppenheimer | Outperform |
| 2023-06-22 | Eingeleitet | Mizuho | Buy |
| 2023-06-07 | Eingeleitet | Jefferies | Buy |
| 2023-05-31 | Eingeleitet | ROTH MKM | Buy |
| 2023-05-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-02-14 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-02-07 | Eingeleitet | UBS | Buy |
| 2022-09-12 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-09-14 | Fortgesetzt | Goldman | Buy |
| 2021-03-02 | Eingeleitet | Cowen | Outperform |
| 2021-03-02 | Eingeleitet | Goldman | Buy |
| 2021-03-02 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Terns Pharmaceuticals Inc Aktie (TERN) Neueste Nachrichten
Analyzing drawdowns of Terns Pharmaceuticals Inc. with statistical toolsJuly 2025 Trade Ideas & Fast Moving Stock Trade Plans - Newser
Terns Pharmaceuticals Inc. stock daily chart insightsIndex Update & Accurate Entry/Exit Alerts - Newser
Sentiment analysis tools applied to Terns Pharmaceuticals Inc.Gap Up & Weekly Momentum Stock Picks - Newser
Using AI based signals to follow Terns Pharmaceuticals Inc.Insider Buying & Stepwise Trade Signal Guides - Newser
Applying chart zones and confluence areas to Terns Pharmaceuticals Inc.2025 Big Picture & Safe Entry Zone Identification - Newser
Will earnings trigger a reversal in Terns Pharmaceuticals Inc.Earnings Miss & Long-Term Growth Stock Strategies - Newser
What institutional flow reveals about Terns Pharmaceuticals Inc.Market Performance Report & Real-Time Buy Zone Alerts - Newser
What makes Terns Pharmaceuticals Inc. stock price move sharplySmart Money Entry Levels - thegnnews.com
Heatmap analysis for Terns Pharmaceuticals Inc. and competitorsLong Term Stock Planner with Safety Checks - Newser
Is Terns Pharmaceuticals Inc. stock bottoming outTechnical Trade Plan with Entry Checklist - Newser
Does Terns Pharmaceuticals Inc. show high probability of reboundFree Breakout Confirmation With Entry Tracker - Newser
Terns Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
Custom strategy builders for tracking Terns Pharmaceuticals Inc.Downside Control Plan With Support Analysis - Newser
Best data tools to analyze Terns Pharmaceuticals Inc. stockVolume Based Swing Signal Prediction Map - Newser
William Blair Has Positive Outlook of TERN FY2025 Earnings - Defense World
How Terns Pharmaceuticals Inc. stock performs during market volatilityFree Portfolio Diversification Stock Ideas - Newser
Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors - inkl
Terns Pharmaceuticals Beats Loss Projections And Ramps Up Drug Trials - Finimize
Terns Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Terns Pharmaceuticals: Earnings Beat and Strategic Pipeline Momentum Signal Long-Term Growth Potential - AInvest
Terns Pharma reports Q2 net loss - MarketScreener
Terns Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - The Manila Times
Terns Pharmaceuticals Inc. stock prediction for this weekFree Weekly Stock Opportunity Radar Scanner - Newser
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Biotech Terns Pharmaceuticals Appoints Chief People Officer, Awards Massive 500,000 Share Option Package - Stock Titan
Is It Too Late to Sell Terns Pharmaceuticals Inc.Top Performing Stock Insights Released Daily - beatles.ru
Should I hold or sell Terns Pharmaceuticals Inc. stock in 2025Discover breakthrough stocks before the crowd - Jammu Links News
How strong is Terns Pharmaceuticals Inc. company’s balance sheetOutstanding capital growth - Jammu Links News
What is the risk reward ratio of investing in Terns Pharmaceuticals Inc. stockTurn volatility into profit opportunities - Jammu Links News
What drives Terns Pharmaceuticals Inc. stock priceAchieve consistent profits with expert advice - Jammu Links News
How does Terns Pharmaceuticals Inc. generate profit in a changing economyTake advantage of unprecedented market momentum - Jammu Links News
What analysts say about Terns Pharmaceuticals Inc. stockCapitalize on proven trading setups - Jammu Links News
What institutional investors are buying Terns Pharmaceuticals Inc. stockGain insights from top financial experts - Jammu Links News
Is Terns Pharmaceuticals Inc. stock overvalued or undervaluedHigh-yield capital appreciation - Jammu Links News
Terns Pharmaceuticals Inc. stock trend forecastMarket Correction Proof Stock Screening Analysis - newser.com
Finanzdaten der Terns Pharmaceuticals Inc-Aktie (TERN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):